Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06832410
PHASE3

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Sponsor: Vertex Pharmaceuticals Incorporated

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Official title: A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-03-31

Completion Date

2027-09-17

Last Updated

2026-03-23

Healthy Volunteers

No

Interventions

BIOLOGICAL

Biological/Vaccine

Infused into the hepatic portal vein.

Locations (7)

Perelman Center for Advanced Medicine - Endocrinology

Philadelphia, Pennsylvania, United States

Montefiore Clinical and Translational Research Center - Endocrinology

Pittsburgh, Pennsylvania, United States

UW University Hospital - Endocrinology

Madison, Wisconsin, United States

Toronto General Hospital - Endocrinology

Toronto, Canada

Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre

Vancouver, Canada

King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology

Riyadh, Saudi Arabia

King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology

Riyadh, Saudi Arabia